AS703206 is a novel, selective, and orally bioactive MEK1/2 inhibitor that has potent cytotoxicity on tumor cells for the majority of patients with relapsed and refractory multiple myeloma (73). The gene discussed is MAP2K1; the disease is plasma cell myeloma.